Abstract: This invention relates to pharmaceutical compositions of 5-alkynyluracil compounds in the form of tablets or capsules.

Abstract: A method of treating a cerebrovascular disease, particularly stroke, is described. A method of treating a cerebrovascular disease includes administering pyridoxal-5′-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyriodoxal-4,5-animal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.

Abstract: This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.

Abstract: A dental care composition for the prophylactic dental hygiene (prophylactic paste) comprises as principal components the following: from 10 to 80% by weight, preferably from 35 to 55% by weight, of a polishing body containing plate shaped rock particles, preferably perlite particles; from 20 to 80% by weight, preferably from 40 to 50% by weight, of a nonionic, preferably polymeric surface active agent; and from 0 to 20% by weight, preferably from 1 to 10% by weight, of an emulsifier or emulsifier blend. Polyethylene glycols (Macrogol) having molecular weights of from 200 to 1,000, preferably of from 200 to 600, are particularly suited as pure compounds or as a blend of different variants having different molecular weights. The dental care composition shows a smooth and soft consistency and has only a weak tendency of being splashed during its application in the mouth.

Abstract: The invention provides conjugates of fatty acids and antiviral agents useful in treating liver disorders.

Abstract: Topical compositions which include urea and carbamide peroxide are described. Compositions having a pH in the acidic range, particularly in the range of about 2.5 to about 9 are also described. Methods for treating dermatological disorders using the composition are also described.

Abstract: The present invention relates to the use of saredutant and of its pharmaceutically acceptable salts for the treatment or prevention of adaptation disorders, bipolar disorders, and dysthymic disorders.

Abstract: This invention relates to the use of a tachykinin receptor antagonist for treating a psychosomatic or a psychoimmunological disorder in a patient.

Abstract: A method of evaluating the effects of administering an external stimuli or treatment such as a psychoactive compound, a drug, or an environmental influence like temperature, noise, vibration, light and similar sensory-perceived influences, on a subject's brain using imaging techniques with positron emission tomography (PET). The method measures cerebral metabolism before and after administering the external stimuli or treatment, and employs a behavioral clamp to control behavioral influences on the subject's brain after administration of the external stimuli or treatment.

Abstract: Novel compositions of matter containing aromatic compounds and terpenoids which are present in and may preferably be derived from the plant Alpinia galanga (Zingiberaceae) show synergistic effects with respect to immunomodulation, and they significantly suppress hypersensitivity reactions. Thus they are used for preparing medicaments for these purposes and, more specifically, for the treatment or prevention of IgE mediated allergic reactions and conditions, such as asthma, allergic rhinitis, a topic eczema or anaphylaxis, and autoimmune disorders, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis or psoriasis, as well as for the alleviation of pain. They can for example be formulated into pharmaceuticals, cosmetics or dietary supplements. A method of preparing such compositions from Alpinia galanga is also described.

Abstract: A composition to stop hair-loss and a method of making said composition with a base of paraffin oil, pure alcohol and fur of otters or minks. This composition is oily and is applied on the part of the head which suffers from hair falling. The remaining on the head is 2-3 days without hair washing with shampoos but only with tap water. The hair washing should be done every 7-14 days. The minimum duration of therapy is 2 months.

Abstract: A composition is described, which comprises a cationic, hydrophilic, amine containing cationic derivatives of native chitosan; bound to an anionic scavenger substance, which is either (a) selected from the group consisting of anionic ethylene amine compounds, tetraazacycloalkane-N,N,N,N-tetraacetic acids; and polymer derivatives of porphyrines, or, (b) in the case of use in an UV radiation absorbing formulation, an antiviral, antifungal or anti-inflammatory formulation, an endogenous compound wherein cationic derivatives of native chitosan are not covalently bound to DTPA or EDTA; the amount of EDTA exceeds 0.5 wight percent; and taurine and taurine derivatives are not present.

Abstract: A method for the treatment of mania in bipolar disorder using derivatives of valproic acid and 2-valproenic acid amides having the following structures: wherein R1, R2, and R3 are independently the same or different and are hydrogen, a C1-C6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3, or a compound containing a valproic or a 2-valproenic moiety, as well as pharmaceutical compositions comprising these derivatives or compounds.

Abstract: The invention provides a method for modulating attentive cognition comprising administering a compound that alters intraneuronal carbonic anhydrase activity thereby affecting establishment of a theta rhythm. The metabolic pathway of the compound preferably involves bicarbonate-mediated GABAergic depolarization. The term “attentive cognition” is meant to encompass memory formation, learning, spatial memory, and attention. The modulating may be stimulating, or the compound may have the multiple effects of inhibiting intraneuronal carbonic anhydrase activity, establishment of a theta rhythm, and memory acquisition. The invention further provides a method of modulating memory and attention comprising switching theta rhythm on and off, the switching comprising potentiating or inhibiting intraneuronal carbonic anhydrase activity.

Abstract: An aqueous neutral to mildly alkaline metal bicarbonate solution is disclosed. The solution comprises metal bicarbonate dissolved in the solution, the metal bicarbonate comprising bicarbonate anions and metal cations. In addition there is a pH adjusting agent in the solution in an amount whereby the solution is at a neutral to mildly alkaline pH. Also disclosed is a process of preparing an aqueous neutral to mildly alkaline metal bicarbonate solution comprising bicarbonate anions and metal cations. The process comprises reacting a compound selected from the group consisting of metal carbonate, metal carbonate hydroxide, metal oxide, metal hydroxide and any mixture thereof with an effective concentration of a pH adjusting agent to produce the aqueous neutral to mildly alkaline metal bicarbonate solution, wherein the pH adjusting agent is present in an amount whereby the solution is at a neutral to mildly alkaline pH.

Abstract: This invention relates to treatment or alleviation of a disease, condition or disorder selected from inflammatory bowel disease, Chron's disease, colitis ulcerosa, Coeliac disease, dermatitis herpetiformis, dermatomyositis, enteritis allergia, erytherma nodosum leprosum, ileitis regionalis, psoriasis, purpura, scleritis or scleroderma by administering to a living body certain imidazole, triazole, or 1,4-dihydropyridine derivatives.

Abstract: The invention is directed to methods for treating conditions mediated by by P38&agr; kinase using compounds of the formula wherein Ar1 and Ph are limited to specific embodiments or wherein the compound of formula (3) is a compound set forth in FIGS. 1A-1T.

Abstract: Methods are disclosed for the treatment and prevention of obesity, weight gain, and eating disorders. The methods comprise the administration of racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof.

Abstract: Compounds and methods are provided to treat inflammatory conditions with certain A2A adenosine receptor antagonists.

Abstract: The invention features the treatment of depression using kappa opioid receptor antagonists.